IL5 and cancer: Events that satisfied with the criteria of event incidence in anti-IL5 treatment group ≥2 times incidence in placebo group and event number ≥ 3 included: anxiety, asthenia, elevated blood creatinine, constipation, heightened thermal perception, hyperhidrosis, influenza-mimicking sickness, large intestinal polyps, muscle spasms, presyncope, procedural pain, perennial rhinitis, stomatitis, exclusively in the benralizumab cohort; unspecified local site reactions singularly in the mepolizumab cohort; malignant neoplasms, pharyngolaryngeal pain solely within the reslizumab cohort.